| HS Code | 262147 |
| Product Name | drug applicator Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable |
| Product Type | Drug Applicator |
| Grade | Pharma Grade API |
| Dosage Forms | Tablet, Capsule, Granule, Injection |
| Route Of Administration | Oral, Injectable |
| Application | Pharmaceutical drug delivery and application |
| Material | Medical-grade polymer, stainless steel |
| Sterility | Sterile or non-sterile options |
| Packaging | Blister pack, vial, syringe, sachet |
| Storage Conditions | Cool, dry, protected from light |
| Shelf Life | 24 to 36 months |
| Certification | GMP, ISO 13485 |
| Origin | China |
| Moq | Negotiable |
| Customization | OEM/ODM available |
As an accredited drug applicator Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged in 25 kg double-lined, sealed fiber drums, suitable for pharmaceutical API, oral and injectable manufacturing, with tamper-evident liner. |
| Container Loading (20′ FCL) | Container Loading (20′ FCL): securely stowed pharma-grade API drug applicator for tablet, capsule, granule, injection, oral, and injectable product handling. |
| Shipping | Pharma-grade API shipments follow GDP and IATA/ADR rules. Products travel in sealed, UN-approved, tamper-evident, validated packaging with temperature control (2–8°C or 15–25°C) and data loggers. Documentation includes MSDS, CoA, customs papers, and chain-of-custody records. Secure, insured transport supports tablet, capsule, granule, oral, and injectable applications. |
| Storage | Store the pharma-grade API in a cool, dry, well-ventilated, secure area away from direct sunlight, heat, moisture, and ignition sources. Keep in original, tightly sealed, labeled containers at controlled room temperature (15–25°C), unless otherwise specified. Segregate oral and injectable grades to prevent cross-contamination. Protect from incompatible substances; follow GMP, safety, and manufacturer storage instructions. Do not store near food, feed, or personal care products. |
| Shelf Life | Shelf life typically 24–36 months for pharma-grade API; varies by drug, oral/injectable form, packaging, and storage. Follow supplier COA. |
The pharma-grade API is first passed through a conical mill fitted with a 610 µm rasp screen operated at 1,200 rpm to break agglomerates and normalize bulk density. The milled fraction is blended with direct-compression diluents such as microcrystalline cellulose and anhydrous dicalcium phosphate. Direct-compression API loading is typically limited to 10–25 wt% because flow and compaction are governed by the excipient skeleton. When drug loading exceeds 30 wt%, tablet weight RSD increases and capping defects become measurable on a rotary press. Higher-load formulations are shifted to wet granulation or roller compaction rather than forcing the powder into a direct-compression design.
Pre-blend lubrication is performed with magnesium stearate at 0.25–1.0 wt%. Quantities above 1.0 wt% reduce core hardness by 20–40% and prolong disintegration because the hydrophobic lubricant coats the API and disintegrant surfaces. The final blend is compressed on a rotary press with 16–24 stations, pre-compression force 2–5 kN, main compression force 8–30 kN for 8 mm round biconcave tooling, and dwell time 20–50 ms. Hardness is maintained at 60–120 N and friability is tested according to USP <1216> with an acceptance threshold of ≤1.0%. Disintegration is evaluated by USP <701> in 37 ± 2 °C water; immediate-release cores must disintegrate within 15 min. Dissolution is performed by USP <711> Apparatus II at 50 rpm, with the Q value defined by the finished drug product monograph.
Film coating follows core compression in a perforated pan with inlet air at 60–70 °C, bed temperature 38–42 °C, atomizing pressure 0.8–1.2 bar, and pan speed 4–10 rpm. Coating solids are applied at 2.0–4.0 wt% weight gain. Process validation must demonstrate that coating does not shift dissolution at the S1 stage and that moisture uptake remains below 1.0% when cores are stored at 25 °C/60% RH for 72 h. Pre-drying is required if the compression suite exceeds 60% RH, because moisture transfer into the API phase alters compactability and friability.
Capsule filling on a dosator or tamping-pin machine imposes a different set of bulk-flow requirements than tablet compression. The API is pre-blended with lactose monohydrate and pregelatinized starch, and the final powder must maintain a Carr index of 15–25% and a Hausner ratio below 1.35. For low-dose capsule formulations, the API is geometrically diluted in three stages to achieve blend uniformity RSD ≤5.0% before the final 5 min blending step. A glidant such as colloidal silicon dioxide is added at 0.2–0.5 wt% when the API surface is highly electrostatic or when the blend is transferred through gravity-fed hoppers.
On a tamping-pin capsule filler operating at 120,000–150,000 capsules/h, target fill weight is 250–500 mg for size 0 capsules. Tamping pin compression force is set between 50–100 N per station, and fill weight RSD is maintained below 2.0% across the batch. Filled capsules are passed through a weight checker that rejects units outside ±3.0% of target. Bulk powder is stored at 25 °C/35% RH and loss on drying is controlled to ≤2.0%. In-process samples are tested every 30 min for weight variation and every 60 min for dissolution using USP <711>. Capsule shell compatibility is confirmed by storage at 40 °C/75% RH for 30 days; shell embrittlement, deformation, or cross-linking is considered unacceptable. For high-dose capsule formulations above 40 wt% API, roller compaction with slugging pressure 4–8 kN/cm is used to densify the API and reduce fill volume.
In high-shear wet granulation, the endpoint is defined by power consumption and impeller torque rather than time alone. The API is loaded intragranularly at 20–50 wt% with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and a binder solution of hypromellose or povidone K30 at 3–6 wt% solids. Granulation liquid is added at 20–40 g/min per kg of dry mix while the chopper runs at 1,500–2,500 rpm and the main impeller at 100–200 rpm. If granulation moisture exceeds 18.0 wt%, the wet mass adheres to the bowl wall, torque signal becomes unstable, and drying time extends beyond 45 min. The optimum endpoint for this formulation class is commonly observed at 12.0–16.0 wt% moisture, corresponding to a granule size D50 of 150–400 µm after wet sieving through a 2.0 mm screen.
The wet granules are dried in a fluid bed at inlet temperature 60–75 °C until loss on drying reaches 1.0–3.0 wt%. Dried granules are milled through a 1.0–1.6 mm screen at 800–1,200 rpm. For sachet filling, the granule fraction retained on an 850 µm sieve should be below 5.0% and fines passing a 125 µm sieve should be below 15.0% to maintain acceptable flow on vertical form-fill-seal equipment. The sachet filler operates at 60–100 strokes/min with fill weight RSD ≤2.5%. Seal seams are tested for leaks by vacuum decay after sealing. Stability samples are stored at 25 °C/60% RH and 40 °C/75% RH in accordance with ICH Q1A(R2), and moisture-sensitive granules are packed with a desiccant when the primary package water vapor transmission rate exceeds 0.5 g/m²/day.
In aseptic liquid injectable manufacturing, the API solubility–pH profile determines buffer molarity, terminal sterilization feasibility, and filter train configuration. The API is dissolved in Water for Injection at 1–20 mg/mL in a stainless steel vessel jacketed at 15–25 °C. Phosphate or citrate buffer is used at 10–50 mM to hold pH within 5.0–7.5 after final dilution. Tonicity is adjusted with sodium chloride or dextrose to 285–320 mOsm/kg. The solution is pre-filtered through a 0.45 µm polyethersulfone membrane and then sterile-filtered through two 0.22 µm membranes in series. Filter integrity is validated by bubble point or diffusion test according to ASTM F838-20. Bacterial challenge data for the membrane must demonstrate a log reduction value of at least 7 for Brevundimonas diminuta ATCC 19146.
Filling is performed in an ISO 14644-1:2015 Class 5 critical zone with unidirectional airflow of 0.36–0.54 m/s. The vial size is typically 2R, 6R, or 10R, and fill volume is 0.6–5.0 mL. Residual oxygen in the headspace is controlled by nitrogen purging to ≤2.0%. For thermostable APIs, terminal sterilization at 121 °C for 15 min with a sterilizing F0 value of ≥8 min is preferred over filtration. For heat-labile APIs, terminal sterilization is not applicable, and aseptic processing is controlled by media fill tests with a target contamination rate below 0.1%. Released units are tested for particulate matter by USP <788> and for bacterial endotoxins by USP <85>. The endotoxin limit is calculated as K/M where K is 0.5 EU/mg for intrathecal routes and 5.0 EU/kg for common parenteral routes. Published data for this specific API configuration is limited where the impurity profile exceeds ICH Q3D elemental threshold values.
| Dosage form | Test designation | Acceptance threshold |
|---|---|---|
| Tablet core | USP <1216> | Friability ≤ 1.0% |
| Tablet core | USP <701> | Disintegration ≤ 15 min |
| Capsule | USP <905> | Acceptance value ≤ 15 |
| Capsule | USP <921> | Loss on drying ≤ 2.0% |
| Granule/sachet | USP <731> | Loss on drying 1.0–3.0% |
| Injectable solution | USP <788> | ≥ 10 µm: ≤ 6000/container; ≥ 25 µm: ≤ 600/container |
| Injectable solution | USP <85> | Endotoxin ≤ product-specific K/M |
Phosphate buffer is avoided when the API forms insoluble calcium or aluminum salts; in that case citrate or acetate is selected. Batch release is conducted under 21 CFR 211.165, sterility is verified by USP <71>, and package integrity is verified by USP <1207>. The filling line must also comply with the cleanroom monitoring requirements of 21 CFR 211.42 and the aseptic processing expectations of EU GMP Annex 1: 2022.
For freeze-dried injectable dosage forms, the API is formulated with a crystalline bulking agent and an amorphous stabilizer. Mannitol is used at 2–5 wt% to provide a crystalline matrix, while sucrose or trehalose is used at 2–10 wt% as a lyoprotectant. The solution is filtered as described for liquid injectables and filled into vials at 1–5 mL per container. The freezing stage uses a shelf ramp rate of 0.5–1.0 °C/min to reach -40 °C, with a hold time of 2–4 h. Annealing is introduced when mannitol crystallization is incomplete; a hold at -20 °C for 1–2 h reduces vial breakage and collapse temperature variation. Primary drying shelf temperature is set at -20 to -10 °C under chamber pressure of 50–150 mTorr. Product temperature must remain below the collapse temperature, which is determined by freeze-drying microscopy. Published data for this specific API configuration is limited, but the formulation class generally exhibits a collapse temperature between -25 and -15 °C.
Secondary drying is performed at 25–40 °C for 4–8 h at 50–100 mTorr. Residual moisture is measured by USP <921> coulometric Karl Fischer titration with a limit of ≤1.0%. Reconstitution time is measured after adding 5–10 mL of Water for Injection; the target is ≤60 s with gentle swirling. Container closure integrity is verified by vacuum decay or dye ingress per USP <1207>. Acceptable cake appearance is defined as absence of meltback, cracking, shrinkage exceeding 3.0% of original fill height, or collapse at the vial bottom.
For oral liquid and extemporaneous powder-for-suspension applications, the API is micronized or wet-milled until the volume-weighted D90 falls below 15 µm. Particle size is measured by laser diffraction according to USP <429>. Suspension viscosity is controlled with xanthan gum at 0.3–0.6 wt% and microcrystalline cellulose/carmellose sodium at 1.0–2.0 wt%. The pH is buffered to 4.5–6.5 to maintain chemical stability and zeta potential below -30 mV for electrostatic stabilization. Preservative efficacy is tested by USP <51>; a typical aqueous formulation contains methylparaben 0.1% and propylparaben 0.02%.
Redispersibility is evaluated after storage at 25 °C/60% RH for 7 days and 14 days. The sedimentation volume F is measured in a graduated cylinder and should remain ≥0.9 after 60 s of manual inversion. If D90 is above 15 µm, sedimentation accelerates and the settled layer forms a hard cake that fails the redispersibility test. The powder blend for reconstitution is filled into amber glass bottles at 60–100 g per unit; dry powder loss on drying is kept below 1.0%. The reconstituted suspension is stored at 2–8 °C and used within 14 days according to ICH Q1A(R2) bracketing stability data. Compounding activities follow USP <795> and the applicable component identity and purity requirements of 21 CFR 211.84.
Competitive drug applicator Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618963613625 or mail to sales10@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8618963613625
Email: sales10@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
The drug applicator model AP-610 is specified as a pharmaceutical-grade API dosing applicator for metered introduction of active pharmaceutical ingredients into tablet, capsule, granule, and injectable manufacturing trains. The system comprises two parallel contact paths: a 316L stainless-steel hopper with twin concave screw feeder for solid oral dosage intermediates, and a gamma-irradiated single-use fluid circuit with peristaltic pump for aqueous and solvent-based injectable APIs. The dry path is rated for free-flowing powders and handled granules with a hopper capacity of 60 L and gravimetric resolution of 0.1 g; the liquid path handles batch volumes from 2 L to 200 L with a dosing accuracy of ±0.5% of target volume after calibration to ISO 17025 reference instruments. Containment for OEB 4 is provided by split-valve docking, inflatable seals, and negative-pressure dust extraction at −50 Pa relative to room; OEB 5 operation is available with an additional high-integrity glovebox interface. The equipment incorporates a recipe-managed batch log with user access levels and audit trail under 21 CFR Part 11. Unlike open scoop transfer or vented drum feeders, the AP-610 does not require product-specific tooling for dry-to-wet changeover; however, elastomer seal replacement and surface sanitization extend turnaround to 45–60 min. Published cross-vendor side-by-side performance data for this exact model are limited; qualification is conducted under site-specific protocols aligned with 21 CFR Part 210/211, 21 CFR Part 11, ICH Q7 Chapter 5, and EU GMP Annex 1.
The primary difference is simultaneous in-line solid and liquid dosing within a single containment boundary. Conventional loss-in-weight feeders deliver powders at similar gravimetric accuracy but require separate aseptic filling pumps for injectable lines and do not incorporate a closed split-valve charge interface. Open manual transfer is faster for small campaigns but introduces no electronic capture of dispensed mass, exposes operators to dust, and cannot demonstrate a validated OEB 4 containment rating. Ventless drum feeders reduce room dust but retain larger residual powder inventory at the drum interface; the AP-610 split-valve cartridge minimizes hold-up mass to less than 1.5% of nominal hopper charge for free-flowing granules. The injectable circuit is differentiated from standard peristaltic pump sets by a pre-assembled gamma-irradiated line with break-resistant aseptic connectors and a 0.2 µm sterilizing-grade membrane filter positioned downstream of the pump; this configuration avoids an additional aseptic transfer step into the filling machine surge vessel.
Solid-dose applications are served by a loss-in-weight twin concave screw feeder with interchangeable screws of 20 mm, 25 mm, and 32 mm diameter and a volumetric cup alternative for free-flowing granules above 0.8 g/cm³ bulk density. The load cell assembly is calibrated to a display resolution of 0.1 g and is shielded from press vibration via damped mounting brackets; the feed rate is controlled from 0.5 kg/h to 120 kg/h with a target mass accuracy of ±0.5% for free-flowing powders and ±1.2% for cohesive APIs with Carr index up to 25. The hopper has a usable volume of 60 L and is fitted with a horizontal counter-rotating agitator to reduce ratholing in APIs with flow function coefficient below 3.0 kPa. API discharge is directed into tablet press feed frames, capsule filling machines, high-shear granulator bowls, or bin blenders through a flexible connection with integrated inert gas purge; the purge gas meets ISO 8573-1:2010 class 1 particle, class 2 water, and class 1 oil limits. Flow behavior is characterized by USP ⟨1174⟩ angle of repose and ASTM D6128-16 shear cell methods; results are used to select screw geometry and agitator speed.
For cohesive APIs with flow function coefficient below 2.0 kPa, a twin-screw feeder without agitation may discharge in pulses. The AP-610 addresses this by coupling an overhung agitator shaft with a horizontal auger and by varying screw speed in closed-loop against weigh scale mass loss. Scale drift from press vibration is suppressed by isolating the hopper frame from the floor using spring-damper mounts with a natural frequency below 5 Hz. Loss-in-weight accuracy is not available during refill phases; the controller switches to volumetric mode and resumes gravimetric correction after refill. This behavior is critical on tablet lines where die-fill variation above 2% RSD affects tablet weight uniformity. On tablet lines, the AP-610 is positioned above the press feed frame and dispenses directly into the hopper using a loss-on-refill algorithm; this avoids press flood and maintains die-fill consistency. For capsule filling, the equipment interfaces with dosator-type machines and operates in semi-continuous replenishment mode, with a dosing precision requirement of not more than ±2% RSD across 10 consecutive aliquots when filling at 50,000 capsules/h. For granule service, the discharge uses a reduced-velocity spiral to transfer granules into a fluid-bed dryer or coating pan without measurable increase in fines; sieve fraction retained above 0.5 mm is monitored by USP ⟨786⟩ particle size distribution estimation. Wet granulation above 12% w/w moisture is excluded from the dry path; pre-dry to loss-on-drying below 5% w/w before transfer is required.
For injectable formulation trains, the AP-610 liquid path is supplied as a gamma-irradiated single-use assembly with a stepper-driven peristaltic dosing pump and a 0.2 µm sterilizing-grade membrane filter. The fluid contact materials are platinum-cured silicone, polypropylene, and gamma-stable polyethylene. The system delivers batch volumes from 2 L to 200 L at linear velocity from 0.1 m/s to 1.5 m/s, with post-filter hold-up volume below 0.35 L per disposable set. Sterility assurance is specified at SAL 10⁻⁶ by terminal gamma irradiation of the assembled fluid path under ISO 11137; filter integrity is tested after use by bubble point and diffusive flow methods based on the 0.2 µm grade. Aseptic docking to filling machines occurs through single-use aseptic connectors in a Grade A unidirectional airflow zone; the surrounding environment may be ISO Class 7 under EU GMP Annex 1 with the fill point at ISO Class 5. Injectable dosing uses a peristaltic pump head with occlusion set at 2.5 N/cm² tube contact pressure; the pump is calibrated gravimetrically for each batch with a two-point calibration across the target flow rate. Fill volume accuracy is ±0.5% or ±0.2 mL, whichever is greater, when measured by buoyancy-corrected mass. The single-use set includes a 0.45 µm prefilter upstream of the sterilizing-grade membrane to reduce particle load; the sterile boundary is confirmed by bubble point testing using alcohol-specific pressure limits. Post-use integrity test failures above 0.1% of batches require quarantine and evaluation of filling line sterility.
Unlike stainless-steel injectable dosing pumps, the single-use path eliminates cross-contamination risk between campaigns and reduces cleaning validation burden; however, it introduces per-batch consumable cost and extractables data requirements. The AP-610 can be configured with either the single-use path or a clean-in-place/steam-in-place stainless steel liquid path for high-volume single-product campaigns. Simultaneous dry and injectable operation is not validated because the solid-dust purge air and aseptic liquid zones cannot share the same containment boundary without additional airflow segregation.
Cleaning validation surfaces on the dry path are electropolished 316L stainless steel with surface roughness Ra ≤ 0.4 µm. Product-contact components are removable without tools for swab sampling and visual inspection. The acceptance limit for residual API on dry-path surfaces is based on a 10 ppm carryover calculation or permitted daily exposure limits, whichever is lower; a default swab limit is established at 1.0 µg/cm² for products with a low health-based exposure limit. For the single-use injectable path, the cleaning requirement is replaced by disposal; lot-specific documentation includes endotoxin below 0.25 EU/mL for water-contact materials, USP Class VI biological reactivity data, and extractables profiles generated according to USP ⟨1663⟩ under worst-case solvent exposure. The AP-610 changeover from dry to injectable service requires 45–60 min for seal replacement, surface wipe-down, and calibrated pump cassette exchange. The dry path is not validated for excipients with bulk density below 0.15 g/cm³ or for materials with particle size below 1 µm without secondary containment due to dust loading. The liquid path is not validated for volatile organic solvents with vapor pressure above 10 kPa at 25 °C unless the pump cassette is enclosed in an exhaust-ventilated zone.
| Standard/Regulation | Application | AP-610 compliance condition | Verification evidence |
|---|---|---|---|
| 21 CFR Part 210/211 | cGMP for finished pharmaceuticals | Equipment surfaces, cleaning, maintenance | IQ/OQ/PQ protocols executed under site validation master plan |
| 21 CFR Part 11 | Electronic records and signatures | Recipe-controlled dosing, audit trail, role-based access | Software validation package |
| ICH Q7 Chapter 5 | API GMP equipment | Design prevents contamination and permits cleaning | Design qualification and risk assessment documentation |
| EU GMP Annex 1 | Sterile manufacture of injectables | Gamma-irradiated single-use liquid path, Grade A point of fill | SAL 10⁻⁶, filter integrity, environmental monitoring |
| ISO 14644-1 | Cleanroom compatibility | Particle emission below ISO Class 7 operational limit | Particle counter data during dynamic operation |
| ISO 8573-1:2010 | Compressed purge gas | Class 1 particles, class 2 water, class 1 oil | Gas quality certificate |
| USP ⟨1174⟩ | Powder flow characterization | Hopper agitation and screw selection based on flow function coefficient | Shear cell and angle of repose |
| ASTM F838-20 | Membrane filter bacterial retention | 0.2 µm sterilizing-grade filter downstream of pump | Bacterial challenge test and post-use integrity |
Operational boundaries are defined by material type and environmental condition. At relative humidity above 60%, the dry hopper must be purged with dried inert gas to prevent moisture uptake in hygroscopic APIs. Avoid combining the dry path with amine-based cleaning agents because residual amine on stainless steel can accelerate corrosion of downstream dies and promote cross-reactions in some sensitive APIs. The equipment does not replace formulation-specific compatibility testing; it provides a controlled metering and containment interface that must be qualified under the end user’s pharmaceutical quality system. Compared with integrated continuous manufacturing platforms, the AP-610 is a semi-continuous applicator rather than a complete continuous processing line. It does not provide granulation, compression, or filling functions; it meters API into those operations. Compared with mobile drum lifters with split valves, the AP-610 includes integrated gravimetric feedback and batch recording, avoiding manual weigh ticket reconciliation. Its dual-path design is uncommon in conventional applicator products; however, published comparative test data across manufacturer platforms for this specific configuration is limited, and vendor literature should be supplemented with site-specific process capability runs.